Home > Publications database > Using gene-environment interactions to explore pathways for colorectal cancer risk. > print

001     305350
005     20251019023217.0
024 7 _ |a 10.1016/j.ebiom.2025.105964
|2 doi
024 7 _ |a pmid:41076992
|2 pmid
024 7 _ |a altmetric:182380858
|2 altmetric
037 _ _ |a DKFZ-2025-02094
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Bouras, Emmanouil
|b 0
245 _ _ |a Using gene-environment interactions to explore pathways for colorectal cancer risk.
260 _ _ |a Amsterdam [u.a.]
|c 2025
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1760363632_16113
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Colorectal cancer (CRC) is a significant public health concern, highlighting the critical need for identifying novel intervention targets for its prevention.We conducted genome-wide interaction analyses for 15 exposures with established or putative CRC risk [body mass index (BMI), height, physical activity, smoking, type 2 diabetes, use of menopausal hormone therapy, non-steroidal anti-inflammatory drugs, and intake of alcohol, calcium, fibre, folate, fruits, processed meat, red meat, and vegetables], and used interaction estimates to explore pathways and genes underlying CRC risk. The adaptive combination of Bayes Factors (ADABF), and over-representation analysis (ORA) were used for pathway analyses, and findings were further investigated using publicly available resources [hallmarks of cancer, Open Targets Platform (OTP)].A total of 1973 pathways using ADABF, and 840 pathways using ORA, out of the 2950 analysed, were enriched (P < 0.05) for at least one exposure, as well as 1227 genes within the enriched pathways. Data were available for 811/1227 coding genes in the OTP, 241 of which were supported by strong relative abundance of prior evidence (overall OTP score > 0.05). Fifty percent of the genes (617/1227) mapped to at least one hallmark of cancer, most of which (388/617) pertained to the Sustaining Proliferative Signalling hallmark. Our findings reflect previously established pathways for CRC risk and highlight the emerging importance of several less studied genes. Common pathways were found for several combinations of exposures, potentially suggesting common underlying mechanisms.The results of the present analysis provide a basis for further functional research. If confirmed, they may help elucidate the etiological associations between risk factors and CRC risk and ultimately inform personalized prevention strategies.This study was funded by Cancer Research UK (CRUK; grant number:PPRCPJT∖100005) and World Cancer Research Fund International (WCRF; IIG_FULL_2020_022). Funding for grant IIG_FULL_2020_022 was obtained from Wereld Kanker Onderzoek Fonds (WKOF) as part of the World Cancer Research Fund International grant programme. Full funding details for the individual consortia are provided in the acknowledgements.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Colorectal cancer
|2 Other
650 _ 7 |a Gene-environment interactions
|2 Other
650 _ 7 |a Mechanisms
|2 Other
650 _ 7 |a Molecular pathways
|2 Other
650 _ 7 |a Pathway analysis
|2 Other
700 1 _ |a Yu, Ren
|b 1
700 1 _ |a Kim, Andre E
|b 2
700 1 _ |a Markozannes, Georgios
|b 3
700 1 _ |a Murphy, Neil
|b 4
700 1 _ |a Albanes, Demetrius
|b 5
700 1 _ |a Anderson, Laura N
|b 6
700 1 _ |a Barry, Elizabeth L
|b 7
700 1 _ |a Berndt, Sonja I
|b 8
700 1 _ |a Bishop, D Timothy
|b 9
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 10
|u dkfz
700 1 _ |a Burnett-Hartman, Andrea
|b 11
700 1 _ |a Campbell, Peter T
|b 12
700 1 _ |a Carreras-Torres, Robert
|b 13
700 1 _ |a Chan, Andrew T
|b 14
700 1 _ |a Cheng, Iona
|b 15
700 1 _ |a Devall, Matthew A
|b 16
700 1 _ |a Diez-Obrero, Virginia
|b 17
700 1 _ |a Dimou, Niki
|b 18
700 1 _ |a Drew, David A
|b 19
700 1 _ |a Gruber, Stephen B
|b 20
700 1 _ |a Gsur, Andrea
|b 21
700 1 _ |a Hoffmeister, Michael
|0 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f
|b 22
|u dkfz
700 1 _ |a Hsu, Li
|b 23
700 1 _ |a Huyghe, Jeroen R
|b 24
700 1 _ |a Kawaguchi, Eric
|b 25
700 1 _ |a Keku, Temitope O
|b 26
700 1 _ |a Kundaje, Anshul
|b 27
700 1 _ |a Küry, Sébastien
|b 28
700 1 _ |a Le Marchand, Loïc
|b 29
700 1 _ |a Lewinger, Juan Pablo
|b 30
700 1 _ |a Li, Li
|b 31
700 1 _ |a Lynch, Brigid M
|b 32
700 1 _ |a Moreno, Victor
|b 33
700 1 _ |a Morrison, John L
|b 34
700 1 _ |a Newton, Christina C
|b 35
700 1 _ |a Obón-Santacana, Mireia
|b 36
700 1 _ |a Palmer, Julie R
|b 37
700 1 _ |a Papadimitriou, Nikos
|b 38
700 1 _ |a Pellatt, Andrew J
|b 39
700 1 _ |a Peoples, Anita R
|b 40
700 1 _ |a Pharoah, Paul D P
|b 41
700 1 _ |a Platz, Elizabeth A
|b 42
700 1 _ |a Qu, Conghui
|b 43
700 1 _ |a Ruiz-Narvaez, Edward
|b 44
700 1 _ |a Mendez, Joel Sanchez
|b 45
700 1 _ |a Schoen, Robert E
|b 46
700 1 _ |a Stern, Mariana C
|b 47
700 1 _ |a Thomas, Claire E
|b 48
700 1 _ |a Tian, Yu
|0 P:(DE-He78)834e8bc4d74592e3b999100c157215f5
|b 49
700 1 _ |a Um, Caroline Y
|b 50
700 1 _ |a Visvanathan, Kala
|b 51
700 1 _ |a Vodicka, Pavel
|b 52
700 1 _ |a Vymetalkova, Veronika
|b 53
700 1 _ |a White, Emily
|b 54
700 1 _ |a Wolk, Alicja
|b 55
700 1 _ |a Woods, Michael O
|b 56
700 1 _ |a Wu, Anna H
|b 57
700 1 _ |a Gunter, Marc J
|b 58
700 1 _ |a Gauderman, W James
|b 59
700 1 _ |a Peters, Ulrike
|b 60
700 1 _ |a Evangelou, Marina
|b 61
700 1 _ |a Tsilidis, Konstantinos K
|b 62
773 _ _ |a 10.1016/j.ebiom.2025.105964
|g Vol. 121, p. 105964 -
|0 PERI:(DE-600)2799017-5
|p 105964
|t EBioMedicine
|v 121
|y 2025
|x 2352-3964
909 C O |o oai:inrepo02.dkfz.de:305350
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 22
|6 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 49
|6 P:(DE-He78)834e8bc4d74592e3b999100c157215f5
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2025
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EBIOMEDICINE : 2022
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-05-02T08:51:17Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-05-02T08:51:17Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-05-02T08:51:17Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-07
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-07
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b EBIOMEDICINE : 2022
|d 2025-01-07
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-01-07
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-01-07
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie der Krebsfrüherkennung
|x 0
920 1 _ |0 I:(DE-He78)C120-20160331
|k C120
|l Primäre Krebsprävention
|x 1
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)C120-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21